statistiche ricercatore

TOSI, GIOVANNA

Distribuzione geografica

Continente	#
NA - Nord America	12.168
EU - Europa	8.871
AS - Asia	5.358
SA - Sud America	512
Continente sconosciuto - Info sul continente non disponibili	75
AF - Africa	67
OC - Oceania	6
Totale	27.057

Salva come PNG Salva come JPEG

Nazione	#
US - Stati Uniti d'America	11.940
IT - Italia	4.373
SG - Singapore	1.684
UA - Ucraina	1.557
CN - Cina	1.228
VN - Vietnam	892
TR - Turchia	654
DE - Germania	589
SE - Svezia	584
HK - Hong Kong	566
FI - Finlandia	477
BR - Brasile	444
FR - Francia	320
IE - Irlanda	299
GB - Regno Unito	251
RU - Federazione Russa	243
CA - Canada	144
IN - India	100
BD - Bangladesh	60
MX - Messico	58
PL - Polonia	43
JP - Giappone	41
BE - Belgio	33
NL - Olanda	26
ZA - Sudafrica	26
AR - Argentina	23
ES - Italia	23
IQ - Iraq	20
PK - Pakistan	14
KR - Corea	12
LT - Lituania	11
MA - Marocco	11
AE - Emirati Arabi Uniti	10
EC - Ecuador	10
PH - Filippine	10
VE - Venezuela	9
EU - Europa	8
CH - Svizzera	7
IR - Iran	7
PY - Paraguay	7
CO - Colombia	6
CZ - Repubblica Ceca	6
ID - Indonesia	6
KE - Kenya	6
MY - Malesia	6
NG - Nigeria	6
PE - Perù	6
SA - Arabia Saudita	6
UZ - Uzbekistan	6
JO - Giordania	5
TN - Tunisia	5
TW - Taiwan	5
AT - Austria	4
BY - Bielorussia	4
CL - Cile	4
DZ - Algeria	4
HN - Honduras	4
JM - Giamaica	4
LB - Libano	4
MD - Moldavia	4
AU - Australia	3
CR - Costa Rica	3
EG - Egitto	3
IL - Israele	3
KH - Cambogia	3
MT - Malta	3
NP - Nepal	3
PA - Panama	3
RS - Serbia	3
BH - Bahrain	2
CI - Costa d'Avorio	2
DO - Repubblica Dominicana	2
GA - Gabon	2
GR - Grecia	2
GT - Guatemala	2
HR - Croazia	2
NI - Nicaragua	2
NZ - Nuova Zelanda	2
PR - Porto Rico	2
PS - Palestinian Territory	2
TT - Trinidad e Tobago	2
UY - Uruguay	2
AO - Angola	1
AZ - Azerbaigian	1
BB - Barbados	1
BG - Bulgaria	1
DK - Danimarca	1
EE - Estonia	1
GE - Georgia	1
GY - Guiana	1
KW - Kuwait	1
KZ - Kazakistan	1
ME - Montenegro	1
MK - Macedonia	1
NO - Norvegia	1
OM - Oman	1
PT - Portogallo	1
QA - Qatar	1
SV - El Salvador	1
SY - Repubblica araba siriana	1
Totale	26.986

Salva come PNG Salva come JPEG

Città	#
Milan	3.344
Jacksonville	1.193
San Jose	1.088
Singapore	932
Fairfield	928
Ashburn	898
Chandler	783
Woodbridge	609
Hong Kong	558
Wilmington	429
Ann Arbor	424
Houston	414
Izmir	406
Princeton	398
Seattle	390
Beijing	371
Dearborn	366
Council Bluffs	337
Dublin	297
Nyköping	297
Dallas	295
Cambridge	287
Dong Ket	268
Rome	237
Boardman	236
The Dalles	235
Lauterbourg	173
San Mateo	138
New York	134
Los Angeles	108
Ho Chi Minh City	102
Como	91
Santa Clara	89
Toronto	88
Helsinki	84
Chicago	83
Hanoi	79
San Diego	77
Ogden	69
Orem	69
Guangzhou	59
Munich	53
São Paulo	53
Düsseldorf	45
Chennai	40
Tokyo	40
Warsaw	36
Hefei	35
Mexico City	34
Verona	33
Brussels	31
London	31
Manchester	29
Nanjing	28
Frankfurt am Main	26
Hangzhou	25
Norwalk	25
Phoenix	24
Shanghai	23
Turku	22
Boston	21
Kunming	21
Brooklyn	20
Montreal	20
Pune	20
Amsterdam	19
Denver	19
Johannesburg	19
Jinan	18
Columbus	17
Falls Church	17
Stockholm	17
Da Nang	16
Fuzhou	16
San Francisco	16
Washington	16
Shenzhen	15
St Petersburg	15
Atlanta	14
Haiphong	14
Poplar	14
Buffalo	12
Zhengzhou	12
Belo Horizonte	11
Mumbai	11
Brasília	10
Nuremberg	10
Baghdad	9
Changsha	9
Curitiba	9
Kocaeli	9
Naples	9
Ankara	8
Kilburn	8
Las Vegas	8
Miami	8
Nanchang	8
Porto Alegre	8
Querétaro	8
Rio de Janeiro	8
Totale	18.635

Salva come PNG Salva come JPEG

Nome	#
CIITA-driven MHC class ii expressing tumor cells can efficiently prime naive CD4+ TH cells in vivo and vaccinate the host against parental MHC-II-negative tumor cells	273
Boosting the MHC class II-restricted tumor antigen presentation to CD4+ T helper cells: A critical issue for triggering protective immunity and re-orienting the tumor microenvironment toward an anti-tumor state	251
Cytoplasmic Localization of HTLV-1 HBZ Protein: A Biomarker of HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP)	238
Adequate Antigen Availability: A Key Issue for Novel Approaches to Tumor Vaccination and Tumor Immunotherapy	234
Active suppression of the class II transactivator-encoding AIR-1 locus is responsible for the lack of major histocompatibility complex class II gene expression observed during differentiation from B cells to plasma cells	219
Tripartite Motif-Containing Protein 22 Interacts with Class II Transactivator and Orchestrates Its Recruitment in Nuclear Bodies Containing TRIM19/PML and Cyclin T1	219
Cell lineage-specific and developmental stage-specific controls of MHC class-II-antigen expression.	217
Typing of a polymorphic human gene conferring susceptibility to insulin-dependent diabetes mellitus by picosecond-resolved FRET on non-purified/non-amplified genomic DNA	214
Localization, quantification and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	213
A girl with Diabetes and severe Combined Immunodeficiency from Adenosine Deaminase Deficiency	210
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection and specific anti-tumor memory.	208
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a TH1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory	207
The MHC-II transactivator CIITA, a restriction factor against oncogenic HTLV-1 and HTLV-2 retroviruses: similarities and differences in the inhibition of Tax-1 and Tax-2 viral transactivators	207
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	207
CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific anti-tumor memory	206
The MHC class II transactivator: prey and hunter in infectious diseases	205
The MHC-II transactivator CIITA inhibits Tat function and HIV-1 replication in human myeloid cells	205
Picosecond-resolved FRET on non-amplified DNA for identifying individuals genetically susceptible to type-1 diabetes	197
The MHC Class II transactivator CIITA inhibits the persistent activation of NF-kB by Tax-1	197
Localization, quantization and interaction with host factors of endogenous HTLV-1 HBZ protein in infected cells and ATL	196
Autoimmunità e Malattie Autoimmuni	192
Molecular and cellular correlates of the CIITA-mediated inhibition of HTLV-2 Tax-2 transactivator function resulting in loss of viral replication	189
Proteomic analysis of dopamine and α-synuclein interplay in a cellular model of Parkinson's disease pathogenesis	187
Adequate Antigen Availability (AAA) in antitumor immunity: Definition and consequences for novel strategies of tumor prevention and antitumor treatment	185
Assessment of the DQB1-DQA1 complete genotype allows best prediction for IDDM	181
Tumor Immunology meets Immunology: Modified cancer cells as professional APC for priming naÃ¯ve tumor-specific CD4+ T cells	181
The HLA class II transcriptional activator blocks the function of HIV-1 Tat and inhibits viral replication	180
Insight into the molecular mechanism of CIITA-mediated inhibition of HIV-1 and HTLV transactivators	178
The MHC class II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation.	178
A dual defensive role of CIITA against retroviral infections	177
The MHC-II transactivator CIITA inhibits Tax-1-mediated HTLV-1 expression and NF-kB activation	177
Neonatal Fc receptor is involved in the protection of fibrinogen after its intake in peripheral blood mononuclear cells	177
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic virus type 1.	172
Multi-omics discovery of exome-derived neoantigens in hepatocellular carcinoma	171
Time-Resolved Förster Resonance Energy Transfer Analysis of Single-Nucleotide Polymorphisms: Towards Molecular Typing of Genes on Non-Purified and Non-PCR-Amplified DNA	170
New approaches of cancer vaccination and cancer immunotherapy based on the optimal stimulation of tumor-specific, MHC class II-restricted CD4+ T helper cells	168
Associazione tra genotipo HLA-DQ e suscettibilità al Diabete insulino-Dipendente	167
Block of Stat-1 activation in macrophages, undergoing bacterial phagocytosis causes CIITA reduced transcription and consequent impaired antigen presentation	166
MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?	166
Major histocompatibility complex class II transcriptional platform: assembly of nuclear factor Y and regulatory factor X (RFX) on DNA requires RFX5 dimers	162
MHC class II transactivator CIITA inhibits Tax-2-mediated HTLV-2 LTR transactivation and viral replication by binding to and affecting Tax-2 intracellular localization	161
CIITA dependent MHC class II IA expression in tumor cells triggers CD4 T cell protective and long lasting antitumor immunity	161
Fowlpoxvirus recombinants coding for the CIITA gene increase the expression of endogenous MHC-II and Fowlpox Gag/Pro and Env SIV transgenes	161
The MHC-II transactivator CIITA inhibits Tat-mediated HIV-1 LTR transactivation and virus replication in human U937 monocytic cells	160
Tax-1-mediated HTLV-1 replication and NF-kB activation is inhibited by the MHC-II transactivator CIITA	160
HIV-1 Tat mutants in the cysteine-rich region down-regulate HLA class II expression in T lymphocytic and macrophage cell lines	160
HLA-DQ genotype in early onset insulin dependent diabetes mellitus	159
A new strategy of tumor vaccination based on mammary adenocarcinoma cells transduced with the MHC class II transactivator CIITA	159
Tax-1-mediated NF-kB activation is inhibited by the MHC-II transactivator CIITA	159
Distinct regulation of HLA class II and class I cell surface expression in THP-1 macrophage cell line after bacterial phagocytosis	158
Tat protein is an HIV-1 encoded SS-chemochine homolog that promotes migrationand upregulates CCR3 on human FceRI+ cells	158
MHC class II gene regulation: some historical considerations on a still ontogenetic and phylogenetic puzzle	158
Analysis of microchimerism in thyroid autoimmune diseases	158
Highly stable oligomerization forms of HIV-1 Tat detected by monoclonal antibodies and requirement of monomeric forms for the transactivating function on the HIV-1 LTR	156
Apparente dissociazione tra fenotipo DR e genotipo MHC di classe II in IDDM	156
Phosphorylation of CIITA directs its oligomerization, accumulation and increased activity on MHCII promoters	155
Molecular typing of polymorphic genes by time-resolved fluorescence resonance energy transfer	155
Analysis of a combined immunodeficiency patient with defect in MHCII expression (BLS) reveals the presence of several mutant isoforms of RFXANK mRNA	153
Molecular and Cellular Correlates of the CIITA-Mediated Inhibition of HTLV-2 Tax-2 Transactivator Function Resulting in Loss of Viral Replication.	153
The MHC class II transactivator CIITA inhibits the persistent activation of NF-kB by Human T cell Lymphotropic Virus type-1 Tax-1 oncoprotein	150
Distinct subcellular localization of HTLV-1 HBZ oncoprotein in the ATL leukemic and HAM/TSP patients.	150
Role of the HLA-DQ genotype in IDDM susceptibility	149
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1B molecules after mycobacterial phagocytosis	149
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic virus type 1	148
The molecular basis of the inhibition of HTLV-2 retroviral replication by the MHC class II transactivator (CIITA)	147
The Major Histocompatibility Complex Class II Transactivator CIITA Inhibits the Persistent Activation of NF-kappa B by the Human T Cell Lymphotropic Virus Type 1 Tax-1 Oncoprotein	147
Optimal MHC-II-restricted tumor antigen presentation to CD4+ T helper cells: the key issue for development of anti-tumor vaccines	146
Transient internalization and/or block of export to the cell surface of HLA Class II and CD1b molecules after bacterial phagocytosis	146
The MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication	146
Inhibition of Human T-Cell Leukemia virus type 2 (HTLV-2) replication by the suppressive action of CIITA and NF-Y	145
HLA-DQB1 typing of north east italian IDDM patients using amplified DNA, oligonucleotide probes and a rapid DNA-Enzyme Immunoassay (DEIA)	145
CIITA blocks the function of HIV-1 Tat by competing for cyclin T1 and inhibits viral replication	145
CIITA reduced transcription as the cause of HLA class II down-modulation in human macrophages during bacterial phagocytosis	145
The MHC class II transactivator (CIITA): a physiologic inhibitor of HIV1 and HTLV2 retroviral infections	143
The MHC Class II transactivator, CIITA,is a viral restriction factor for human oncogenic retroviruses	142
The MHC class II transactivator (CIITA): a physiologic inhibitor of HTLV-2 retroviral infection.	142
HTLV2 influence on pathways regulating proliferation and death in B cell line BJAB	142
The complex interplay of the DQB1 and DQA1 loci in the generation of the susceptible and protective phenotype for Insulin-Dependent Diabetes Mellitus	142
A new strategy of tumor vaccination based on tumor cells transduced with the MHC class II transactivator CIITA	141
HTLV-2 Tax-2 transactivator increases the expression and the function of its inhibitor CIITA, the master regulator of HLA-II gene transcription	141
Inhibition of human T cell leukemia virus type 2 (HTLV-2) replication by the suppressive action of class II transactivator and nuclear factor Y	140
Expression of MHC class I and class II antigens in pancreatic adenocarcinomas	140
Associazione tra HLA-DQB1 e diabete giovanile analizzata a livello molecolare per Southern e DEIA	139
Cellular and molecular aspects of immune response relevant to autoimmune diseases	139
The MHC-II transactivator CIITA, a viral restriction factor inhibiting the replication of Human T cell Lymphotropic Virus Type 1	139
Tumor treatment by TNF-alpha targeted to tumor vessels and melphalan induces strong adaptive immune response, protection from tumor growth and anti-tumor memory.	137
The MHC class II transactivator, CIITA, blocks the transcriptional activity of both HTLV-2 Tax-2 and HTLV-1 Tax-1	136
The constitutive activation of NF-kB by HTLV-1 Tax-1 oncoprotein is inhibited by the MHC class II transactivator CIITA	136
Host-retrovirus interaction: role of CIITA in the inhibition of HTLV-1 replication and oncogenic potential	135
TPA-mediated down-regulation of MHC class II gene expression in human macrophage precursors by destabilization of the MHC-II transactivator (CIITA) mRNA	134
Human T-cell leukemia virus type II directly acts on CD34+ hematopoietic precursors by increasing their survival potential. Envelope associated HLA class II molecules reverse this effect	132
Efficient antigen presentation and T cell activation by MHC class II molecules of CIITA-transfected epatocarcinoma cells	131
Regulation of HLA antigen expression in HIV infected cells	131
Control of mammary adenocarcinoma growth in vivo by gene therapy with the MHC class II transactivator CIITA	129
Characterization of an epigenetic variant lacking MHC-II inducibility by IFN-g in the promyelocytic cell line THP-1	128
The MHC-II transactivator CIITA is a viral restriction factor against HIV-1 replication	128
HLA-DQ typing for prediction of IDDM? Some "yes" people.	128
HLA class II expression in uninducible hepatocarcinoma cells after transfection of AIR-1 gene product CIITA. Acquisition of antigen processing and presentation capacity.	127
Evidence for a specific post- transcriptional mechanism controlling the expression of HLA-DQ, but not DR and DP molecules	127
The MHC class II transactivator (CIITA): a "physiologic" drug against HIV-1 replication	127
Totale	16.561

Salva come PNG Salva come JPEG

Categoria	#
all - tutte	106.569
article - articoli	0
book - libri	0
conference - conferenze	0
curatela - curatele	0
other - altro	0
patent - brevetti	0
selected - selezionate	0
volume - volumi	0
Totale	106.569

Salva come PNG Salva come JPEG

	Totale	Lug	Ago	Sett	Ott	Nov	Dic	Gen	Feb	Mar	Apr	Mag	Giu
2021/2022	1.489	0	223	152	133	42	48	57	123	83	222	159	247
2022/2023	2.159	252	86	120	258	159	493	0	292	312	63	69	55
2023/2024	4.884	816	801	919	824	877	310	50	40	155	20	9	63
2024/2025	2.562	10	45	483	50	107	108	123	141	313	158	220	804
2025/2026	6.105	492	363	187	862	539	448	1.407	371	620	413	246	157
2026/2027	412	158	254	0	0	0	0	0	0	0	0	0	0
Totale													27.057